Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Paying user area
Try for free
Pfizer Inc. pages available for free this week:
- Balance Sheet: Assets
- Analysis of Short-term (Operating) Activity Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Analysis of Geographic Areas
- Enterprise Value to EBITDA (EV/EBITDA)
- Price to FCFE (P/FCFE)
- Debt to Equity since 2005
- Total Asset Turnover since 2005
- Price to Earnings (P/E) since 2005
- Analysis of Debt
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Pfizer Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Long-term Activity Ratios (Summary)
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
A consistent decline in asset utilization efficiency is evident across the observed period. All three ratios – net fixed asset turnover, total asset turnover, and equity turnover – demonstrate a downward trajectory, although at varying rates. This suggests a decreasing ability to generate sales from investments in assets and equity.
- Net Fixed Asset Turnover
- The net fixed asset turnover ratio experienced a noticeable decrease from 6.12 in April 2022 to 3.24 in December 2025. The decline was most pronounced between July 2022 and December 2023, falling from 6.64 to 3.14. While the ratio stabilized somewhat in subsequent quarters, it did not exhibit any significant recovery, fluctuating between 3.26 and 3.46 before ending at 3.24. This indicates a diminishing ability to generate revenue from fixed assets.
- Total Asset Turnover
- The total asset turnover ratio mirrors the trend observed in net fixed asset turnover, declining from 0.50 in April 2022 to 0.30 in December 2025. The most substantial decrease occurred between April 2022 and December 2023, dropping from 0.50 to 0.26. The ratio remained relatively stable at 0.30 for the final three reporting periods, suggesting a potential leveling off of asset utilization decline, albeit at a lower overall level. This suggests a decreasing efficiency in utilizing all assets to generate sales.
- Equity Turnover
- The equity turnover ratio also exhibits a downward trend, decreasing from 1.12 in April 2022 to 0.72 in December 2025. The rate of decline was relatively consistent throughout the period, with a more pronounced drop observed between April 2022 and October 2023, falling from 1.12 to 0.71. A slight increase to 0.72 was observed in the subsequent two quarters, but the ratio concluded at 0.72, indicating a reduced ability to generate sales from shareholder equity.
The concurrent declines in all three ratios suggest a systemic issue related to asset utilization. Potential contributing factors could include increased asset holdings without corresponding sales growth, decreased operational efficiency, or a shift in business strategy towards less asset-intensive activities. Further investigation is warranted to determine the underlying causes of these trends.
Net Fixed Asset Turnover
| Dec 31, 2025 | Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 31, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Revenues | |||||||||||||||||||||
| Property, plant and equipment, net of accumulated depreciation | |||||||||||||||||||||
| Long-term Activity Ratio | |||||||||||||||||||||
| Net fixed asset turnover1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Net Fixed Asset Turnover, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
1 Q4 2025 Calculation
Net fixed asset turnover
= (RevenuesQ4 2025
+ RevenuesQ3 2025
+ RevenuesQ2 2025
+ RevenuesQ1 2025)
÷ Property, plant and equipment, net of accumulated depreciation
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The net fixed asset turnover ratio demonstrates a clear declining trend over the observed period. Initially, the ratio exhibited values above 6.0, but progressively decreased to approximately 3.24 by the end of the period.
- Initial Period (Apr 3, 2022 – Dec 31, 2022)
- The ratio began at 6.12 and peaked at 6.64 before experiencing a moderate decline to 6.17. This suggests a relatively stable and efficient utilization of fixed assets to generate revenue during this timeframe. Fluctuations likely reflect seasonal sales patterns or short-term operational changes.
- Transitional Phase (Apr 2, 2023 – Oct 1, 2023)
- A more pronounced downward trend commenced in the spring of 2023, with the ratio falling from 5.46 to 3.88. This indicates a weakening relationship between revenue generation and the level of fixed assets employed. The decline could be attributed to factors such as decreased sales volume, increased fixed asset investment without a corresponding revenue increase, or a combination of both.
- Continued Decline (Dec 31, 2023 – Sep 28, 2025)
- The ratio continued its descent, reaching a low of 3.14 in December 2023 and stabilizing around the 3.2 to 3.4 range for the subsequent periods. While the rate of decline slowed, the ratio remained significantly lower than its initial values. This sustained decrease suggests a persistent issue with fixed asset utilization. The most recent value of 3.24 indicates that for every dollar invested in fixed assets, approximately $3.24 in revenue is generated.
- Revenue and Fixed Asset Relationship
- Concurrent analysis reveals that revenues also experienced a decline over the period, although not as consistently as the net fixed asset turnover ratio. The combined effect of decreasing revenues and relatively stable or increasing net fixed assets contributed to the observed reduction in the turnover ratio. The increase in property, plant, and equipment, net of accumulated depreciation, without a proportional increase in revenues is a key driver of this trend.
Overall, the observed trend suggests a diminishing efficiency in utilizing fixed assets to generate revenue. Further investigation is warranted to determine the underlying causes of this decline and to identify potential strategies for improving fixed asset utilization.
Total Asset Turnover
| Dec 31, 2025 | Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 31, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Revenues | |||||||||||||||||||||
| Total assets | |||||||||||||||||||||
| Long-term Activity Ratio | |||||||||||||||||||||
| Total asset turnover1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Total Asset Turnover, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
1 Q4 2025 Calculation
Total asset turnover
= (RevenuesQ4 2025
+ RevenuesQ3 2025
+ RevenuesQ2 2025
+ RevenuesQ1 2025)
÷ Total assets
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The total asset turnover ratio exhibits a clear downward trend over the observed period. Initially, the ratio fluctuated around 0.50 to 0.52 during the first four quarters, before declining significantly in subsequent periods.
- Overall Trend
- A consistent decline in the total asset turnover ratio is apparent. Starting at 0.50 in April 2022, the ratio decreased to 0.30 by December 2025. This indicates a diminishing ability to generate revenue from its asset base.
- Initial Period (Apr 3, 2022 – Dec 31, 2022)
- The ratio remained relatively stable, ranging between 0.50 and 0.52. This suggests consistent efficiency in utilizing assets to generate sales during this timeframe. Revenues were also comparatively higher during this period.
- Transitional Phase (Apr 2, 2023 – Oct 1, 2023)
- A noticeable decrease began in April 2023, falling from 0.48 to 0.32 by October 2023. This coincides with a reduction in revenues, suggesting a weakening relationship between asset levels and sales generation.
- Recent Period (Dec 31, 2023 – Dec 31, 2025)
- The ratio continued its downward trajectory, stabilizing around 0.30 in the most recent quarters. While the rate of decline slowed, the ratio remained significantly lower than its initial values. Revenues also remained relatively stable, but at a lower level than in the initial period.
The sustained decrease in the total asset turnover ratio warrants further investigation. Potential contributing factors could include changes in sales strategies, increased investment in less liquid assets, or a general decline in operational efficiency. The consistent decline suggests that the company is becoming less efficient in utilizing its assets to generate revenue.
Equity Turnover
| Dec 31, 2025 | Sep 28, 2025 | Jun 29, 2025 | Mar 30, 2025 | Dec 31, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Revenues | |||||||||||||||||||||
| Total Pfizer Inc. shareholders’ equity | |||||||||||||||||||||
| Long-term Activity Ratio | |||||||||||||||||||||
| Equity turnover1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Equity Turnover, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).
1 Q4 2025 Calculation
Equity turnover
= (RevenuesQ4 2025
+ RevenuesQ3 2025
+ RevenuesQ2 2025
+ RevenuesQ1 2025)
÷ Total Pfizer Inc. shareholders’ equity
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The equity turnover ratio for the analyzed period demonstrates a consistent downward trend, albeit with some quarterly fluctuations. Initially, the ratio exhibited values above 1.10, indicating that for every dollar of equity, more than $1.10 of revenue was generated. However, subsequent quarters reveal a progressive decline in this metric.
- Overall Trend
- A clear decreasing trend is observed in the equity turnover ratio throughout the period. The ratio decreased from 1.12 in Apr 3, 2022, to 0.72 in Dec 31, 2025. This suggests a diminishing efficiency in utilizing shareholders’ equity to generate revenue.
- Initial Phase (Apr 3, 2022 – Oct 2, 2022)
- The ratio remained relatively stable, fluctuating between 1.08 and 1.16. This initial period suggests a consistent, though not exceptionally high, level of equity utilization. A slight decrease is noticeable from the peak of 1.16 to 1.08.
- Accelerated Decline (Dec 31, 2022 – Oct 1, 2023)
- A more pronounced decline is evident during this phase, with the ratio decreasing from 1.05 to 0.71. This suggests a weakening relationship between equity and revenue generation. The largest single-quarter decrease occurred between Dec 31, 2022 and Apr 2, 2023.
- Stabilization and Recent Performance (Oct 1, 2023 – Dec 31, 2025)
- While the downward trend continued, the rate of decline slowed. The ratio fluctuated between 0.61 and 0.72 during this period. The most recent value, 0.72 as of Dec 31, 2025, indicates that for every dollar of equity, approximately $0.72 of revenue is generated. There is a slight increase from 0.68 in Sep 28, 2025 to 0.72 in Dec 31, 2025.
The consistent decrease in the equity turnover ratio warrants further investigation. Potential contributing factors could include changes in revenue generation strategies, increased equity base without corresponding revenue growth, or shifts in asset utilization. The observed trend suggests a potential need to evaluate the efficiency of equity management and revenue-generating activities.